Comparison of Two Treatment Modalities in Overactive Bladder: a Rapid Overview

Background: Overactive bladder is a syndrome of urgency with the absence of infection and is usually accompanied by frequency and nocturia. Both sacral neuromodulation (SNM) and intravesical botulinum toxin (BTX) injection are used contentiously in overactive bladder after the failure of conservativ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicinski arhiv 2022-12, Vol.76 (6), p.469-472
Hauptverfasser: Mirza, Abdulrahim, Alamoudi, Mohammed, Mirza, Ahmad, Alsubaie, Munirah, Abuzenada, Mohammed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Overactive bladder is a syndrome of urgency with the absence of infection and is usually accompanied by frequency and nocturia. Both sacral neuromodulation (SNM) and intravesical botulinum toxin (BTX) injection are used contentiously in overactive bladder after the failure of conservative management. Objective: We aimed to provide an updated comparative overview of botulinum toxinBTX injection versus sacral neuromodulationSNM in the treatment of overactive bladder. Methods: PubMed and Google scholar databases were explored starting from 2016 to 2022 to obtain relevant articles. English studies on the adult population were included. Results: Six articles included 502 648 participants were included in the current overview. Both BTX and SNM are comparable for the treatment of overactive bladder, with no major complications were reported. However, the use of SNM for refractory overactive bladder after the failure of BTX was more successful and effective and resulted in patient satisfaction compared to the use of BTX after the failure of SNM. Conclusion: Our update provides the latest comparative overview of outcomes of botulinum toxinBTX versus sacral neuromodulationSNM in the treatment of overactive bladder.
ISSN:0350-199X
1986-5961
DOI:10.5455/medarh.2022.76.469-472